0.4630
+0.0120
+(2.66%)
As of 5:15:46 PM GMT+2. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-8,879
-13,978
-21,813
-16,893
-25,749
Investing Cash Flow
99
41
--
-42
52
Financing Cash Flow
3,997
3,230
2,585
9,025
28,712
End Cash Position
2,814
2,341
13,058
32,287
40,203
Capital Expenditure
--
--
-23
-49
-281
Issuance of Capital Stock
--
--
--
295
16,873
Issuance of Debt
5,200
6,300
6,000
11,322
15,956
Repayment of Debt
42
-83
-1,816
-232
-2,924
Free Cash Flow
-8,879
-13,978
-21,836
-16,942
-26,030
12/31/2020 - 2/12/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HQ1.MU Oruka Therapeutics Inc. R
7.35
+4.26%
MVR0.BE Medivir AB
0.1406
+42.16%
RPD.MU Royalty Pharma plc
28.20
0.00%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
P0F.F Egetis Therapeutics AB (publ)
0.2910
-1.52%
ICY.HA Incyte Corp
51.32
-1.57%
MVR0.F Medivir AB (publ)
0.1256
-17.69%
PROT Proteonomix, Inc.
0.0000
0.00%
2HA.F Spero Therapeutics, Inc.
0.6330
+2.59%
05Y.MU Vivoryon Therapeutics NV
1.7140
-1.72%